secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001013762-25-003401
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio FY2024 net loss $42.1M; AD02 top-line data expected June 2025
------------------------------------------------------------------------

- Net loss $42.1M vs $30.0M in FY2023; R&D expenses rose to $33.2M from $20.3M.
- Cash and equivalents $20.9M as of Dec 31, 2024; $22.9M shares outstanding.
- Completed $27.5M equity offering (incl. ~3.9M warrants) and repaid Silicon Valley Bank loan.
- AD02 Phase 2 Alzheimer's trial fully enrolled (208 patients); top-line cognitive results due June 2025.
- CORDStrom planning BLA filing in RDEB in 2025/early 2026, eligible for Priority Review Voucher.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000101376225003401/0001013762-25-003401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000101376225003401/ea0235584-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001013762-25-003401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer